Topgolf Callaway Brands said it will sell a 60% stake in its Topgolf unit to private-equity firm Leonard Green as it turns more focus to its equipment and apparel business.

VanEck Steel ETF will soon switch benchmarks to the MVSLX Index. MVSLX lacks exposure to several emerging markets projected to drive significant steel sector growth over the next 1-2 years. MVSLX is heavily biased towards large market-cap companies and includes companies with significant non-steel business exposure.

Palantir (Nasdaq: PLTR) stock has lost 10% in the last 5 days after fading AI enthusiasm and negativity surrounding insider sales have caught up with a premium valuation.

Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ET

CLEARWATER, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the pricing of its previously announced underwritten public offering of 2,762,431 shares of its common stock at a public offering price of $3.62 per share of common stock, before deducting underwriting discounts and commissions and offering expenses.

PETACH TIKVA, Israel , Nov. 18, 2025 /PRNewswire/ -- Eltek Ltd. (NASDAQ: ELTK), a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards (PCBs), today announced its financial results for the quarter ended September 30, 2025.

Investors are starting to worry about too much AI-related debt issuance

AZOUR, Israel , Nov. 18, 2025 /PRNewswire/ -- Ituran Location and Control Ltd. (NASDAQ: ITRN) announced that the Board of Directors approved the distribution of a cash dividend in the amount of $0.50 per share, totaling approximately US$ 10 million.

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS®) taking place from December 9-12, 2025 at Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, Texas.

Shares of the buy-now, pay-later provider have tumbled since its public trading debut in September.

Data demonstrate a favorable bioavailability profile of INM-901 oral formulation Data will support design and planning of first in human clinical trials Preparing for pre-IND meeting with the FDA Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today announced the successful completion of pharmacokinetic ("PK") studies in large animal models for its Alzheimer's disease candidate INM-901. This marks the first preclinical study in which the oral formulation of INM-901 was administered in …

ATLANTA--(BUSINESS WIRE)--Vestis (NYSE: VSTS), a leading provider of uniforms and workplace supplies, today announced that it will issue its fiscal fourth quarter and full year 2025 results after the market closes on Monday, December 1, 2025. A conference call will be held the following day, Tuesday, December 2, 2025 at 8:30 a.m. ET to review the Company's financial results and conduct a question-and-answer session. A webcast of the conference call and accompanying presentation materials will b.

Joint offering seeks to embed trust and transparency into the lifecycle of tokenized assets, aligning sustainability metrics with the next generation of digital-market infrastructure. Joint offering seeks to embed trust and transparency into the lifecycle of tokenized assets, aligning sustainability metrics with the next generation of digital-market infrastructure.

Collaboration accelerates quantum simulations by orders of magnitude, expanding global access to hybrid quantum computing and advancing the path toward industrial-scale quantum systems GPU-Accelerated QLEO Launch: QPerfect and Quobly unveil the next-generation QLEO emulator, powered by QPerfect's MIMIQ engine and fully compatible with NVIDIA CUDA-Q, delivering up to 100× faster quantum simulations. Bridging Quantum and Classical Systems: The collaboration expands access to hybrid quantum-classical computing, enabling developers and researchers to design, test, and scale quantum algorithms seamlessly across GPU and CPU environments.

The new ETF is designed to provide attractive monthly income while focusing on the long-term total return of common shares of JPMorgan Chase & Co. The new ETF is designed to provide attractive monthly income while focusing on the long-term total return of common shares of JPMorgan Chase & Co.

The biggest thing impacting the EV maker's shares this week highlights its shift to being an AI play.

BCE Inc. is poised for a rebound after a significant dividend cut, improved cash flow, and a strategic U.S. expansion via Ziply Fiber. BCE now retains ~$500 million more quarterly, enabling debt reduction, balance sheet repair, and supporting a sustainable dividend yield. Valuation metrics show BCE trades below historical and peer averages, suggesting ~25% upside potential over the next 2-3 years, excluding organic growth.

Selection underscores QuickLogic's ability to deliver flexible, silicon-proven IP that reduces ASIC risk and shortens design cycles for commercial applications SAN JOSE, Calif. , Nov. 18, 2025 /PRNewswire/ -- QuickLogic Corporation (NASDAQ: QUIK), a developer of embedded FPGA (eFPGA) Hard IP and ruggedized FPGAs, announced today that its eFPGA Hard IP was selected by Chipus for a high performance data center production ASIC that will be fabricated on an industry-proven 12 nm process technology.

First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is interleukin-2 -- cytokine that maintains proper numbers and functions of regulatory T cells to control excessive inflammation Gateway to development of a first-in-kind immunotherapeutic for autoimmune and pro-inflammatory diseases MIRAMAR, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, today announced the first patient was dosed at The Ohio …

Investors still believe in tech. But it worries them as well.